Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imatinib (Gleevec)-induced hepatotoxicity.

Walid S Ayoub1, Stephen A Geller, Tram Tran

  • 1Center for Liver and Kidney Diseases and Transplantation, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.

Journal of Clinical Gastroenterology
|December 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply: Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.

Hepatology communications·2026
Same author

Multiscale zonation-resolved modeling of dose-dependent determinants of acetaminophen-induced liver injury.

Frontiers in pharmacology·2026
Same author

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Hepatology communications·2026
Same author

Clinical signs and symptoms of Wilson disease in a real-world cohort of patients in the United States: a medical chart review study.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

Treatment patterns in a real-world cohort of patients with Wilson disease in the United States.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view.

Nature reviews. Gastroenterology & hepatology·2026

Imatinib, a cancer drug, can cause liver damage (hepatotoxicity). This report details a new case of Imatinib-induced hepatotoxicity, including its histopathology and clinical outcome after drug withdrawal.

Area of Science:

  • Hepatology
  • Oncology
  • Pharmacology

Background:

  • Imatinib (Gleevec) is a crucial targeted therapy for chronic myelogenous leukemia and gastrointestinal stromal tumors.
  • Drug-induced liver injury is a significant concern in clinical practice.
  • Histologically proven Imatinib-induced hepatotoxicity is rare, with limited published cases.

Observation:

  • A 22-year-old female patient developed liver injury during Imatinib treatment.
  • The case involved detailed histopathologic examination of liver tissue.
  • Clinical data documented the patient's course following Imatinib discontinuation.

Findings:

  • This case adds to the scarce literature on Imatinib-induced hepatotoxicity.
  • Histopathological findings provide insights into the mechanism of liver injury.

Related Experiment Videos

  • Discontinuation of Imatinib led to the resolution of liver injury.

    • Implications:

    • Clinicians should be vigilant for potential hepatotoxicity in patients receiving Imatinib.
    • Further research may elucidate the mechanisms underlying Imatinib-induced liver injury.
    • Early recognition and management are crucial for patient outcomes.